Christopher Cannon, MD, Professor of Medicine, Harvard Medical School, discusses the recent topline results from the Vascepa cardiovascular (CV) outcomes trial, REDUCE-IT, a global study of 8,179 statin-treated adults with elevated CV risk. According to a recent announcement from Amarin, REDUCE-IT met its primary endpoint demonstrating a 25% relative risk reduction, to a high degree of statistical significance, in major adverse CV events (MACE) in the intent-to-treat patient population with use of Vascepa 4 grams/day as compared to placebo.
Amarin Corp is the Manufacturer of Vascepa
